51. 全身性強皮症 Scleroderma Clinical trials / Disease details
臨床試験数 : 523 / 薬物数 : 608 - (DrugBank : 156) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 215
| No. | TrialID | Date_ enrollment  | Date_ registration  | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor  | Secondary_ sponsor  | Recruitment_ Status  | Inclusion_ agemin  | Inclusion_ agemax  | Inclusion_ gender  | Target_ size  | Phase | Countries | 
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-194761 | 23/5/2019 | 17/05/2019 | A Phase 3 study of KHK4827 in patients with systemic sclerosis | A Phase 3, placebo-controlled, double-blind comparative study of KHK4827 with an open-label extension period in subjects with systemic sclerosis who have moderate to severe skin thickening | Systemic sclerosis | Intervention name : KHK4827 INN of the intervention : Brodalumab Dosage And administration of the intervention : 210 mg Q2W, SC Control intervention name : Placebo INN of the control intervention : - Dosage And administration of the control intervention : 210 mg Q2W, SC  | Kyowa Kirin Co., Ltd. | NULL | complete | 18 | 70 | BOTH | 100 | Phase 3 | Japan | 
| 2 | JPRN-JapicCTI-173686 | 06/10/2017 | 29/08/2017 | A Phase 1, open-label, multiple-dose study of KHK4827 in subjects with systemic sclerosis | A Phase 1, open-label, multiple-dose study of KHK4827 in subjects with systemic sclerosis | systemic sclerosis | Intervention name : KHK4827 INN of the intervention : brodalumab Dosage And administration of the intervention : SC, 210 mg Q2W Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : -  | Kyowa Kirin Co., Ltd. | NULL | complete | 18 | 70 | BOTH | 6 | Phase 1 | Japan |